ArticleNature communications2023
Structural basis of selective cannabinoid CB
Open access · goldFull text read
In one paragraph
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
16.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 67 citations in OpenAlex.
- (+)-Trans-Cannabidiol Is an Agonist at Human CBPharmacology research & perspectives · 2026Article
- Efficacy of Cannabinoids in Improving Nutritional Outcomes in Chemotherapy Patients: A Scoping Review.Cureus · 2026Review
- Library Docking for Cannabinoid-2 Receptor Ligands.Journal of medicinal chemistry · 2026Article
- CNR1 and CNR2 Cannabinoid Receptor Mutations in Cancer Cells.Current issues in molecular biology · 2026Article
- Orally bioavailable CBResearch square · 2026Article
- Dynamic mechanism for subtype selectivity of endocannabinoids.The Journal of biological chemistry · 2026Article
- Single-position ligand modifications tune CBChemical science · 2026Article
- Structural basis for positive allosteric regulation of CB2 receptor.Nature communications · 2026Article
- Leveraging machine learning for selective cannabinoid ligand discovery: methods, challenges, and opportunities.Expert opinion on drug discovery · 2026Review
- A Reinforcement Learning-Guided Genetic Algorithm Integrating Medicinal Chemistry-Inspired Molecular Transformations.Journal of chemical information and modeling · 2026Article
- Library docking for Cannabinoid-2 Receptor ligands.bioRxiv : the preprint server for biology · 2026Article
- Article
- Drug Repurposing: Conversion of the Peripherally Restricted HIV Protease Inhibitor Amprenavir to Potent, Selective, and CNS-Penetrant Agonists for the Cannabinoid Receptor 2.Journal of medicinal chemistry · 2026Article
- Pentadecanoic acid (C15:0) and cardiovascular disease: A narrative review.World journal of cardiology · 2025Review
- Cannabichromene, a key non-psychotropic phytocannabinoid in treatment of major depressive disorder: in silico and in vivo explorations.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- The Endocannabinoid System in the Development and Treatment of Obesity: Searching for New Ideas.International journal of molecular sciences · 2025Review
- Evaluation of the Cytotoxic Activity of Nanostructured Lipid Carrier Systems for Fatty Acid Amides and Silk Fibroins in Breast Cancer Cell Lines.Molecules (Basel, Switzerland) · 2025Article
- Advances in cannabinoid receptors pharmacology: from receptor structural insights to ligand discovery.Acta pharmacologica Sinica · 2025Review
- Structural basis of THC analog activity at the Cannabinoid 1 receptor.Nature communications · 2025Article
- Repolarization of inflammatory macrophages into reparative stage targeting cannabinoid receptor2: a potential perspective to dampen lung injury/ARDS.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 3 countries.
Xiaoting Li *iHuman Institute, ShanghaiTech University, Shanghai, 201210, China.ORCID 0000-0001-6431-3143
Hao Chang *iHuman Institute, ShanghaiTech University, Shanghai, 201210, China.ORCID 0000-0003-1684-8201
Jara Bouma *Division of Drug Discovery and Safety, Leiden Academic Center for Drug Research, Leiden University, Oncode Institute, Leiden, the Netherlands.ORCID 0000-0002-6572-6158
Laura V de PausDepartment of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Oncode Institute, Leiden, the Netherlands.ORCID 0000-0002-5624-8457
Partha MukhopadhyayLaboratory of Cardiovascular Physiology and Tissue Injury, National Institute of Health/National Institute on Alcohol Abuse and Alcoholism, Rockville, MD, USA.
Janos PalocziLaboratory of Cardiovascular Physiology and Tissue Injury, National Institute of Health/National Institute on Alcohol Abuse and Alcoholism, Rockville, MD, USA.
Mohammed MustafaDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.
Cas van der HorstDivision of Drug Discovery and Safety, Leiden Academic Center for Drug Research, Leiden University, Oncode Institute, Leiden, the Netherlands.ORCID 0000-0002-5859-5348
Sanjay Sunil KumarDivision of Drug Discovery and Safety, Leiden Academic Center for Drug Research, Leiden University, Oncode Institute, Leiden, the Netherlands.ORCID 0000-0001-7386-5636
Lijie WuiHuman Institute, ShanghaiTech University, Shanghai, 201210, China.
Yanan YuiHuman Institute, ShanghaiTech University, Shanghai, 201210, China.
Richard J B H N van den BergDepartment of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Oncode Institute, Leiden, the Netherlands.
Antonius P A JanssenDepartment of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Oncode Institute, Leiden, the Netherlands.ORCID 0000-0003-4203-261X
Aron LichtmanDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.
Zhi-Jie LiuiHuman Institute, ShanghaiTech University, Shanghai, 201210, China. liuzhj@shanghaitech.edu.cn.ORCID 0000-0001-7279-2893
Pal PacherLaboratory of Cardiovascular Physiology and Tissue Injury, National Institute of Health/National Institute on Alcohol Abuse and Alcoholism, Rockville, MD, USA. pacher@mail.nih.gov.ORCID 0000-0001-7036-8108
Mario van der SteltDepartment of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Oncode Institute, Leiden, the Netherlands. m.van.der.stelt@chem.leidenuniv.nl.ORCID 0000-0002-1029-5717
Laura H HeitmanDivision of Drug Discovery and Safety, Leiden Academic Center for Drug Research, Leiden University, Oncode Institute, Leiden, the Netherlands. l.h.heitman@lacdr.leidenuniv.nl.ORCID 0000-0002-1381-8464
Tian HuaiHuman Institute, ShanghaiTech University, Shanghai, 201210, China. huatian@shanghaitech.edu.cn.ORCID 0000-0002-6132-2068
Leiden University · NLShanghaiTech University · CNNational Institute on Alcohol Abuse and Alcoholism · USVirginia Commonwealth University · US
Funding
Mechanism of oxidative/nitrosative stress and inflammation-induced tissue injuryZIAAA000375 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI PACHER, PAL · 2009 to 2025
$27.8MAbstract
Cannabinoid CB
Indexed as
Cannabinoid Receptor AgonistsCannabinoidsCyclohexanolsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2Receptors, Cannabinoid3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanolCannabinoid Receptor AgonistsCannabinoidsCyclohexanolsHU 308Receptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2Receptors, Cannabinoid
Identifiers
What OpenQuestion holds
Textfull text, public
LicenceCC BY
measurements read203
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.